Generate Biomedicines (NASDAQ:GENB) Shares Down 6.7% – What’s Next?

Generate Biomedicines Inc (NASDAQ:GENB)’s stock price dropped 6.7% during trading on Thursday. The company traded as low as $14.11 and last traded at $14.01. Approximately 725,887 shares were traded during mid-day trading, a decline of 13% from the average daily volume of 834,337 shares. The stock had previously closed at $15.02.

Wall Street Analyst Weigh In

GENB has been the topic of several analyst reports. Wall Street Zen raised Generate Biomedicines from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. Weiss Ratings raised shares of Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Generate Biomedicines in a research report on Tuesday, September 8th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $26.40.

Generate Biomedicines Stock Performance

The stock has a fifty day moving average of $15.53 and a 200-day moving average of $14.34. The company has a market cap of $1.76 billion and a PE ratio of -8.61.

Generate Biomedicines (NASDAQ:GENB) last released its earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The firm had revenue of $6.31 million during the quarter. As a group, equities analysts anticipate that Generate Biomedicines Inc will post -2.29 EPS for the current fiscal year.

Institutional Trading of Generate Biomedicines

Institutional investors and hedge funds have recently modified their holdings of the stock. Braidwell LP purchased a new position in shares of Generate Biomedicines during the second quarter valued at $55,398,000. State Street Corp purchased a new stake in Generate Biomedicines during the second quarter worth $8,883,000. The Manufacturers Life Insurance Company bought a new stake in Generate Biomedicines during the 2nd quarter valued at $1,431,000. Bank of New York Mellon Corp purchased a new position in shares of Generate Biomedicines in the 2nd quarter valued at $967,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Generate Biomedicines in the 2nd quarter valued at $530,000.

About Generate Biomedicines

Generate Biomedicines is a biotechnology company focused on discovering and developing protein-based medicines. The company uses generative artificial intelligence, machine learning and laboratory-based biological research to design new therapeutic proteins and identify candidates with potential applications in a range of diseases.

Its platform, often described as a generative biology approach, is designed to model biological systems and create proteins with desired characteristics rather than relying solely on modifying naturally occurring molecules.